Connect with us

Healthcare

Windlas Biotech Limited (windlas): Q4 & FY26 Results: Revenue Up 18%, EPS at Rs. 31.60

Windlas Biotech Limited (WINDLAS) reports Q4 & FY26 results with 18% YoY revenue growth, Rs. 31.60 EPS, and strong net liquidity.

kuldeep yadav tradealone

Published

on

Windlas Biotech Limited Windlas Q4 FY26 Results

Windlas Biotech Limited (WINDLAS) delivered another year of strong performance in FY26, reporting a 19% YoY revenue growth to Rs. 904 Cr. The Q4 FY26 revenue increased 18% YoY to Rs. 238 Cr, demonstrating the company’s focus on scalability, durability, and profitability. The company’s highest post-listing EPS of Rs. 31.60 highlights its financial health. Windlas Biotech Limited closed FY26 with a strong net liquidity position of Rs. 251 Cr and a net debt-free status.

Consistent Growth

The company’s revenue growth was driven by its strategic investments in Plant-4 and Plant-5, which received GMP certification from the Philippines. The Injectables and Plant-2 Ext. facilities continue to drive overall business growth. Plant-6 has achieved mechanical completion and is on track for commercialization by H1 FY27.

Operational Efficiency

Windlas Biotech Limited’s operational efficiency is reflected in its adjusted EBITDA and PAT. The adjusted EBITDA grew 26% to Rs. 121 Cr, and the PAT grew 31% to Rs. 83 Cr for FY26. In Q4 FY26, adjusted EBITDA stood at Rs. 33 Cr, and PAT at Rs. 23 Cr. The company also generated Rs. 105 Cr of net operating cash flows, reinforcing its strong financial position.

Looking ahead, Windlas Biotech Limited remains optimistic about growth prospects and focuses on enhancing long-term value for shareholders through diversification, operational efficiencies, and expansion of dosage forms.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Windlas Biotech Limited

Windlas Biotech Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

WINDLAS
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING SUPPORT
76
Fundamental
76
Technical
76
Overall

1W -0.97%
1M +9.11%
3M +5.92%
P/E: 31.5 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Windlas posts a 0.2% three-month gain, but softens in the last few weeks. Thin margins at 7.7% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The business compounds revenue at 17.7% and profits at 17.0% CAGR. That is strong double-digit growth on both counts. The stock gives back 11.4% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 17.7% and profits at 17.0% CAGR — a genuinely strong business. Nevertheless, the stock drops 0.2% in three months. The market sells the stock, not the story. Watch whether that changes at the next earnings. Check Fundamentals of Windlas Biotech Limited.

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
APPROACHING RESISTANCE
52
Fundamental
56
Technical
54
Overall

1W -1.66%
1M +6.46%
3M -12.15%
P/E: 121.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

GLENMARK

Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301

Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.

Pranab Tyagi at TradeAlone

Published

on

Glenmark Pharmaceuticals Limited Glenmark IND Submission

Glenmark Pharmaceuticals Limited (GLENMARK) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. The focus keyword, Glenmark Pharmaceuticals Limited GLENMARK IND Submission, highlights this significant milestone in the company’s oncology pipeline. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and natural killer (NK) cells.

Advancement in Multispecific Oncology Pipeline

The IND submission marks an important step in advancing Ichnos Glenmark Innovation’s (IGI) multispecific oncology pipeline into clinical development. ISB 2301, engineered using IGI’s proprietary BEAT® Multispecific Platform, combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. This pentaspecific molecule is designed to address biological heterogeneity and immune-suppressive features of solid tumors.

Planned Phase 1 Clinical Trial

IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. Preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, showing favorable pharmacokinetic and tolerability profiles in non-human primates. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of ISB 2301 in patients with advanced solid tumors.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GLENMARK
Healthcare › Drug Manufacturers - Specialty & Generic
BREAKOUT
78
Fundamental
94
Technical
86
Overall

1W -1.16%
1M +19.72%
3M +13.62%
P/E: 51.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Glenmark rises 12.3% over three months, with buying pressure holding steady. The PEG of 0.77 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.77 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Continue Reading

Drug Manufacturers - General

Sai Parenterals Limited (saiparent) Acquires Majority Stake in Bion Therapeutics’ Prescription Business

Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics’ prescription business, adding 16 brands and enhancing market presence.

Pranab Tyagi at TradeAlone

Published

on

Sai Parenterals Limited Saiparent November 2026 Acquisition

Sai Parenterals Limited (NSE: SAIPARENT) has announced a strategic move to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. This acquisition, executed through its wholly owned subsidiary SP Analytics Private Limited, is expected to be finalized before the end of this month. The transaction will be an all-cash deal, significantly strengthening Sai Parenterals’ presence in India’s prescription market.

Strategic Benefits

The acquisition of Bion Therapeutics will add 16 established brands and around 250 field staff to Sai Parenterals, enhancing its competitive position in the domestic pharmaceutical landscape. Bion’s extensive infrastructure provides immediate access to a broader market, integrating with Sai Parenterals’ manufacturing capabilities to ensure assured supply, consistent quality, and improved margins.

Operational Integration

Bion’s portfolio, currently manufactured by third parties, will progressively transfer to Sai Parenterals’ accredited facilities, which hold TGA-Australia and WHO-GMP accreditations. This move will allow Bion’s brands to leverage Sai Parenterals’ development pipeline and Noumed’s dossier library, offering a wider portfolio to its existing doctor coverage. The critical-care injectable facility, SAICRITI, due for completion in August 2027, will provide a route into hospital and critical-care segments for Bion’s injectable brands.

Forward-Looking Vision

Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, emphasized the strategic importance of this acquisition in converting development capability into branded revenue. The value flows in both directions, with Bion’s portfolio transferring to Sai Parenterals’ facilities and Sai Parenterals’ development pipeline broadening Bion’s market offerings. Further particulars of the transaction will be disclosed at the appropriate stage.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SAIPARENT
Healthcare › Drug Manufacturers - General
CONSOLIDATING DOWN
72
Fundamental
66
Technical
70
Overall

1W -0.83%
1M +3.88%
3M -9.1%
P/E: 89 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Sai falls 8.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 57.9% and profits at 48.3% CAGR. Both numbers are exceptional. The stock gains 3.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 57.9% and profits at 48.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 8.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

Continue Reading

Trending

Exit mobile version